The VerifyNow System assesses response to antiplatelet therapies, such as aspirin, Plavix and GP IIb/IIIa inhibitors. As response to these drugs varies, the tests help physicians ensure their patients on antiplatelet medications are receiving the optimal benefit.
“We’re extremely excited to see distribution of our VerifyNow System reach Israel and Cyprus. We have chosen these partners based on their demonstrated expertise and knowledge of our markets in their respective territories,” said Timothy I. Still, president and CEO of Accumetrics. “These partnerships continue to emphasize our focus on expanding our global distribution channels, and support our vision of providing physicians worldwide access to critical information for managing their cardiovascular patients on antiplatelet therapies.”
